Revelation Biosciences, Inc., a clinical-stage life sciences company focused on optimizing health through rebalancing inflammation, has announced the pricing of a $4 million public offering. The company will issue 3,640,000 shares of its common stock, alongside warrants to purchase up to 14,560,000 shares at a public offering price of $1.10 per share and associated warrant. The warrants, exercisable following stockholder approval, will expire five years after the initial exercise date. The proceeds are intended for the development of product candidates, completion of a Phase 1b clinical study, drug supply manufacturing, preclinical work, and other corporate purposes. Roth Capital Partners is acting as the sole placement agent for the offering.